Preliminary studies on isolates of Clostridium difficile from dogs and exotic pets by Andrés-Lasheras, S. et al.
RESEARCH ARTICLE Open Access
Preliminary studies on isolates of
Clostridium difficile from dogs and exotic
pets
Sara Andrés-Lasheras1, Inma Martín-Burriel2, Raúl Carlos Mainar-Jaime1, Mariano Morales1,3, Ed Kuijper4,
José L. Blanco5, Manuel Chirino-Trejo6 and Rosa Bolea1*
Abstract
Background: Clostridium difficile infection (CDI) is recognised as an emerging disease in both humans and some
animal species. During the past few years, insights into human CDI epidemiology changed and C. difficile is also
considered as an emerging community-acquired pathogen. Certain ribotypes (RT) are possibly associated with
zoonotic transmission. The objective of this study was to assess the presence of C. difficile in a population of pets
and to characterise the isolates.
Results: Faecal samples from a total of 90 diarrhoeic dogs and 24 from exotic animal species (both diarrhoeic and
non-diarrhoeic) were analysed. Clostridium difficile was isolated from 6 (6.7%) dogs and one reptile sample (4.2%). Four
(66.7%) of the six dog strains were capable of producing toxins. Four known different RTs were detected in dogs (010,
014, 123 and 358) and a new one was found in a faecal sample of an exotic animal. This new RT isolate was negative
for all toxin genes tested and belonged to sequence type 347 which has been proposed as a Clade-III member.
Importantly, two dog strains showed a stable resistance to metronidazole (initial MIC values: 128 and 48 μg/ml).
Conclusions: The results obtained in this study suggest the implementation of antimicrobial susceptibility surveillance
programs to assess the prevalence of metronidazole resistance in dogs; molecular studies to elucidate C. difficile
metronidazole resistance mechanisms are warranted. Based on the similarity between the ribotypes observed in dogs
and those described in humans, the zoonotic transmission should be further explored. Furthermore, exotic animals
have shown to harbor uncommon C. difficile strains which require further genomic studies.
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Background
Clostridium difficile is a bacterium capable of producing
enteric disease in different animal species included
humans. Toxigenic C. difficile strains are the most com-
mon cause of antibiotic-associated diarrhoea in people
from developed countries through the synthesis of toxins
A and B, its main virulence factors [1]. The epidemi-
ology of C. difficile has changed in the last 15 years and
it is now recognised as an emerging pathogen in both
humans and animals. It is also considered an emerging
community-acquired pathogen likely associated with a
zoonotic and/or foodborne transmission [2].
Animals are an important source of many infectious dis-
eases for humans. About 75% of emerging infectious dis-
eases are zoonoses [3], and it is thought that pets could be
implicated in the transmission of C. difficile to humans
since similar genotypes have been recovered from them
and humans [4]. Among the strains isolated from dogs,
there are several ribotypes of international interest, such
as RT078, RT014/020 and RT045 [5]. Likewise, exotic ani-
mals can act as vectors of many zoonotic diseases, includ-
ing enteric diseases, and several zoonotic outbreaks have
been associated with the trade of this type of animal spe-
cies (either in a legal or illegal way) as their international
trade has increased recently [6]. However, there is limited
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information about toxigenic C. difficile carriage in exotic
animals in the scientific literature [7].
Dogs can develop diarrhoea due to different bacteria
or virus infections (e.g. Salmonella spp., Campylobacter
spp., Clostridium perfringens, C. difficile, or coronavirus),
intestinal parasites (e.g. Giardia spp.), nutritional factors,
inflammation, allergies or neoplasia [8, 9]. So far, the
role of C. difficile in canine enteric disease is still unclear
due to the presence of toxigenic strains or their toxins in
asymptomatic animals and the failure to reproduce CDI
in healthy dogs with and without antibiotic treatment [9,
10]. It can be isolated from 0 to 57% of healthy dogs
with no diarrhoea [11]. However, there are several stud-
ies which have reported an association between the pres-
ence of C. difficile toxins in faeces with diarrhoea, as
well as with outbreaks of haemorrhagic diarrhoea in vet-
erinary hospitals [9, 12–14]. But it is still unknown
whether C. difficile represents an opportunistic patho-
gen, or simply a fortuitous finding in this animal species
[10].
There is limited information about antimicrobial sus-
ceptibilities of C. difficile strains obtained from dogs or
exotic animal species [7, 15]. Metronidazole, and less fre-
quently vancomycin, are used to treat CDI in dogs follow-
ing the recommendations for human episodes [16]. These
drugs are also commonly used to treat different kinds of
exotic animal infections as well. The isolation of
metronidazole-resistant strains or strains showing low
susceptibility to this drug is growing in both humans and
animals [17], particularly in ribotypes 010 and 001 [18,
19]. In addition, resistance to metronidazole is heteroge-
neous and therefore C. difficile can show reduced suscep-
tibility to this drug, which can be related to recurrent CDI
cases [20].
The objective of this study was to assess the presence of
C. difficile in a population of diarrhoeic dogs and exotic
animal species (both diarrhoeic and non-diarrhoeic), and
to characterise the C. difficile isolates by the presence of
toxin genes, their PCR-ribotype and toxinotype, and also
their antimicrobial susceptibility pattern.
Methods
Sampling
Diarrhoeic stool samples from dogs, submitted to a veter-
inary diagnostic laboratory located in the Zaragoza, NE of
Spain were used. The samples were collected between Oc-
tober 2011 and November 2012. All of them were ana-
lysed for the presence of C. difficile by microbiological
culture in our laboratory. The specimens were collected
using commercial swabs with Amies transport medium
(Deltalab, Barcelona, Spain) by veterinary staff at the time
of the animal clinical examination. The samples originated
from primary veterinary clinics located at different Span-
ish regions (Table 1). All of them were sent under
refrigerated conditions to the diagnostic laboratory, ar-
rived within the 24 h after collection, and were kept at −
80 °C until C. difficile culture was performed. In addition
to C. difficile, faecal samples were analysed for other en-
teric pathogens upon request of the veterinarian in charge
of the case (analysis carried out in the diagnostic labora-
tory; data not published). Dogs were classified by their age
(0–4 months puppy; 5–12 months juvenile; 13–72 months
adult; ≥73 months mature), gender, breed, location and
presence/absence of dysbiosis. In addition, other labora-
tory data were recorded for each case when available.
Additionally, faecal samples were cultured from exotic
animals from a veterinary clinic laboratory specialised in
that kind of animals located in Barcelona, NE of Spain.
The sampling period covered June and July 2013. The
specimens derived from diarrhoeic and non-diarrhoeic
animals. Each sample was taken by the veterinary staff
during the examination of the animals and submitted to
our laboratory under refrigerated conditions within the
first 24 h after collection. As in the dog’s study, the sam-
ples were kept at − 80 °C until the culture for C. difficile
was performed. Exotic animals were identified by species
and grouped into three main animal categories (i.e. rep-
tiles, small mammals and birds). No other data were
available except being sick or not.
Bacterial culture and strain characterisation
The isolation of C. difficile, molecular characterisation of
the strains obtained (i.e. tpi housekeeping and toxin genes
detection by PCR, identification of non-toxigenic strains,
and PCR-ribotyping) and antimicrobial susceptibility test-
ing was performed as described elsewhere [21]. The
variability of the genes coding for toxins A and B (A3 and
B1 fragments respectively) of toxigenic strains obtained
was assessed through toxinotyping by PCR-RFLP [22].
Besides, those strains which showed unexpected results,
i.e. negative PCR results for tcdA and tcdB genes and also
non-toxigenic assay, were further studied by toxinotyping
as well (A1, A2, A3, B1, B2 and B3 fragments) to test the
possible presence of toxin gene fragments.
Multilocus sequence typing (MLST) technique was used
for characterisation of strains which did not belong to a
known PCR ribotype. By this technique, seven housekeep-
ing loci are studied by PCR and subsequent sequenced,
providing a sequence type (ST) profile and a clade [23]
based on these genes alleles [24]. A maximum likelihood
tree with 1000 bootstrap replicates was constructed based
on the Kimura 2-parameter model [25]. A total of 37
strains were used for this purpose: one from this study
(E6), 17 from previous works carried out by our team (Hu,
RC and RF isolates; data not published for Hu isolates)
[26], and 19 from the PubMLST database to provide a
context for C. difficile population (ST1, ST3, ST5, ST11,
ST32, ST37–39, ST41, ST67, ST96, ST122, ST177–181,
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ST200 and ST206). Initial tree(s) for the heuristic search
were obtained by applying the Neighbour-Joining method
to a matrix of pairwise distances estimated using the Max-
imum Composite Likelihood approach. Evolutionary ana-
lyses were conducted in MEGA7 [27].
Additionally, seven serial passages over 14 days were per-
formed on Brucella blood agar plates without antibiotics in
order to assess the stability of the initial metronidazole-
resistant isolates, i.e. those which showed a breakpoint
≥32 μg/ml [28]. Then, the MIC to metronidazole was tested
again by Etest as described above. Resistance was consid-
ered stable when the MIC of metronidazole against C. diffi-
cile remained (within ±1 dilution) after the passages.
Resistance was considered unstable when resistant strains
became susceptible (˂32 μg/ml) after the passages.
Statistical analysis
The prevalence of C. difficile was estimated for dogs and
exotic pets separately. When possible, comparisons of C.
difficile prevalence among the factors considered for dogs
were assessed by univariable logistic regression. Thus, the
outcome variable was the presence/absence of C. difficile
and the explanatory variable was the corresponding factor
(age, gender, breed, location and dysbiosis). Significance
was set at p-values ≤0.05.
Results
Bacterial isolation and molecular characterization
Faecal samples from a total of 90 dogs were analysed. The
samples came from 42 different veterinary clinics located in
11 different Autonomous Communities in Spain, most of
them (86.7%) located in the north/northeast of the country.
The median age of dogs was 9.5 months (range 1–156) and
52.2% of the animals were females. A total of 29 dog breeds
were included and grouped as large (e.g. German shep-
herd), medium (e.g. Beagle) and small size (e.g. Yorkshire).
Clostridium difficile was isolated from 6 (6.7%) out of the 90
dogs analysed. All these results are summarised in Table 1.
Table 1 Characteristics of the dog population included in the study
Variable Number samples (%) Number positive




Female 47 (52.2) 3 (6.4) 2 (4.2)
Male 43 (47.8) 3 (7) 2 (4.6)
Agec 0.42
0–4 m 25 (27.8) 2 (8) 2 (8)
5–12 m 21 (23.3) 0 0
13–72 m 21 (23.3) 2 (9.5) 2 (9.5)
≥ 73 m 9 (10) 0 0
Spanish geographical region 0.77
North 36 (40) 2 (5.6) 2 (5.6)
Northeast 42 (46.7) 3 (7.1) 2 (4.8)
Centre 7 (7.8) 1 (14.3) 0
Southeast 5 (5.5) 0 0
Season 0.71
Winter 31 (34.4) 1 (3.2) 1 (3.2)
Spring 9 (10) 1 (11.1) 1 (11.1)
Summer 3 (3.3) 0 0
Fall 47 (52.2) 4 (8.5) 2 (4.3)
Breedd 0.63
Large 40 (44.4) 2 (5) 1 (2.5)
Medium 29 (32.2) 2 (6.9) 2 (6.9)
Small 13 (14.4) 0 0
Dysbiosis 0.66
No 28 (31.1) 1 (3.6) 0
Yes 62 (68.9) 5 (8.1) 4 (6.5)
CD Clostridium difficile; aUnivariable logistic regression; bpercentages calculated from the total number of samples; cage unknown for 14 samples (two of them are
positive to non-toxigenic C. difficile); dbreed unknown for eight samples (one of them is positive to toxigenic C. difficile and another one to non-toxigenic C. difficile)
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Four (66.7%) strains with toxin genes (Table 2) yielded an A
+B+CDT- genotype in all cases. Non-toxigenic strains
showed a positive result with lok3/1 primers. Four different
ribotypes were detected, and all toxigenic strains belonged
to toxinotype 0 (Table 2).
The four (100%) toxigenic C. difficile positive dogs
showed dysbiosis and faeces without mucus, while only
57 (67.8%) out of 84 of the C. difficile negative dogs
showed this problem. However, this difference was not
statistically significant (p = 0.3). No relationship was ob-
served between the presence of C. difficile and any of
the other factors considered (Table 1). None of the dogs
presenting toxigenic C. difficile yielded a positive result
for another enteric pathogen (data not shown).
Twenty-four faecal samples derived from exotic species,
10 (41.7%) from diarrhoeic animals, 11 (45.8%) from non-
diarrhoeic animals and three with unknown clinical data
(12.5%). Fifteen (62.5%) were birds, mainly composed of
different species of psittacines, 3 (12.5%) small mammals
(lagomorphs, mustelids and rodents) and 6 (25%) saurop-
sid reptiles. Only one sample (4.2%; E6 strain, Table 2) be-
longing to a reptile (Pogona vitticeps) yielded a positive
culture result for C. difficile. It was negative for all toxin
genes tested (tcdA, tcdB, cdtA and cdtB) but also negative
to the non-toxigenic PCR (see Additional file 1) and to the
toxinotyping scheme (A1, A2, A3, B1, B2 and B3 frag-
ments) (see Additional files 2 and 3). Interestingly, this
isolate represented a new PCR-ribotyping type (Table 2)
and belonged to ST347, which was recently proposed as a
Clade C-III member [29] (Fig. 1).
Antimicrobial susceptibility testing
All dog strains were susceptible to tetracycline and
vancomycin (range between 0.064–0.38 μg/ml for vanco-
mycin), whereas resistance to clindamycin, erythro-
mycin, metronidazole and moxifloxacin varied (50%,
33.3%, 33.3% and 16.7% respectively) (Table 3). Two
strains showed a MDR phenotype to clindamycin,
erythromycin and metronidazole; resistance to metro-
nidazole was unchanged and stable after a serial number
of passages on antibiotic-free medium (Table 2). The
MICs of the remaining strains (n = 4) to metronidazole
varied between 0.19–0.38 μg/ml.
One strain (D24) was considered resistant (and stable)
to metronidazole with a heterogeneous pattern. After
the 24 h incubation time, the isolate showed a fully sus-
ceptible phenotype to metronidazole (MIC 0.38 μg/ml)
(Fig. 2, growth II or GII; improved contrast image), but
a subpopulation of tiny colonies (Fig. 2, growth I or GI)
was present inside the initial inhibition halo exhibiting a
higher MIC (8 μg/ml). MIC results remained unharmed
after three extra days of incubation. After observing
these results, the growth I and II were sub-cultured sep-
arately in blood agar without antibiotics in order to re-
peat the susceptibility test to metronidazole following
the protocol described above. After 48 h of incubation,
both isolates showed metronidazole resistance (MICs
128 and 192 μg/ml, GI and GII respectively). The metro-
nidazole resistance stability test was performed only for
GI (Table 2). A similar phenomenon was observed for
this D24 isolate regarding its susceptibility to erythro-
mycin and clindamycin. However, the subpopulations
growing inside the initial halo reached a fully resistant
phenotype to both antibiotics after 48 h of incubation.
When the susceptibilities were repeated for the two dif-
ferent growths, both showed a fully resistant phenotype
to these antimicrobials after 24 h.
The reptile C. difficile isolate (E6) was susceptible to
all antimicrobial drugs (MICs range 0.19–2 μg/ml)
tested except to tetracycline, for which a decreased sus-
ceptibility was found (MIC 6 μg/ml).
Discussion
Clostridium difficile was isolated from 6.7% (6/90) of
dogs with diarrhoea, but only four strains were toxigenic
(66.7%). Overall, this prevalence was somewhat lower
than that reported in previous studies of diarrheic dogs
or dogs with various digestive disorders (29% -[30],
12.1% -[15] and 10% -[31]). However, these differences
can be explained by variations of the study design (i.e.
number and type of dogs included, geographical loca-
tion, age distribution, etc.). They may be also due to the
fact that samples were collected in veterinary clinics all
around Spain and submitted to a veterinary diagnostic
laboratory before arriving at our laboratory. It is well
known that the survival rate of C. difficile may be com-
promised if faecal samples are stored under aerobic con-
ditions [32]. It has also been reported that toxin-positive
samples can yield a culture-negative result for C. difficile
from dog faecal samples [9]. In addition, there were sev-
eral limitations in this study to consider: the lack of the
Table 2 Molecular characterization of Clostridium difficile isolates
IDa Toxin genes NTSb Toxinotype RT ST MIC0/MICS to MZ
c
D18 tcdA, tcdB NA 0 014 – –
D21 – + NA 123 – –
D24d tcdA, tcdB NA 0 014 – 128/96
D57 tcdA, tcdB NA 0 358 – –
D66 tcdA, tcdB NA 0 014 – –
D83d – + NA 010 – 48/32
E6 – – NA New 347 –
RT PCR-ribotype, ST sequence type, MIC0: initial minimal inhibitory concentration
to metronidazole (μg/ml), MICS: minimal inhibitory concentration to metronidazole
after repeated passages (μg/ml), MZ metronidazole, NA not applicable, D dog’s
strain, E exotic species strain; aisolate identification; bnon-toxigenic strains PCR; cini-
tial metronidazole-resistant isolates stability experiment results; dmetronidazole and
multidrug-resistant isolates
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information on previous or ongoing antibiotic treatment
data at the time of sampling.
Among the ribotypes detected in this study the most
frequent was the epidemic RT014 (3/6) which has been
widely isolated from CDI cases in humans in several Euro-
pean countries, including Spain [33]. This ribotype has
been also isolated from different animal species and types
of samples, including dogs, retail meat and water [34–36].
Only one out of the six isolates from this study belonged
to the non-toxigenic ribotype 010 which has been largely
associated with dogs [18, 37, 38] and occasionally isolated
from humans [5]. These results add more evidence to a
Fig. 1 Molecular phylogenetic analysis (maximum likelihood method) from concatenated MLST alleles. Clostridium difficile isolates corresponding
to our collection are showed with a circle. ST, sequence type; Hu, human isolate; RC, rat intestinal content isolate; 5754, sow vagina isolate; RF,
environmental rat faeces isolate; E, exotic animal isolate
Table 3 In vitro activity of six antimicrobials against the Clostridium difficile dog isolates
Antimicrobial agent Range (μg/ml) Breakpointa (μg/ml) Number resistant isolates (%)
Clindamycin 0′016–256 ≥8b 3/6 (50)
Erythromycin 0′016–256 ≥8 2/6 (33.3)
Metronidazole 0′016–256 ≥32b 2/6 (33.3)
Moxifloxacin 0′02–32 ≥8b 1/6 (16.7)
Tetracycline 0′016–256 ≥8 0
Vancomycin 0′016–256 ≥32 0
aThe breakpoints for resistance established by the Clinical and Laboratory Standards Institute (CLSI) for anaerobic bacteria are those marked by b [50]. The
breakpoint for tetracycline was ≥8 μg/ml [51]. The remaining breakpoints were based on the literature [7]
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possible inter-species C. difficile transmission as previ-
ously observed other authors [39, 40]. However, to the au-
thor’s knowledge, there are no available data regarding the
epidemiology of ribotypes 123 and 358 in Europe, which
would suggest that they are not very common genotypes
neither in humans nor in animals.
Metronidazole is the first choice to treat non-severe
CDI in humans [41] and a very common treatment for
CDI and Giardia spp. infections in dogs [16, 42]. Overall,
the frequency of resistant C. difficile isolates to metronida-
zole is still low (0%–18%) [17], and even lower after la-
boratory strain manipulation [28]. In this study, a higher
proportion of strains (33.3%, ribotypes 010 and 014) re-
vealed stable resistance to metronidazole. An increase in
the number of metronidazole-resistance C. difficile isolates
has been observed for the last years in both humans and
animals strains [17]. Interestingly, higher MIC averages to
this drug are frequently associated with the non-toxigenic
RT010 [19]. Thus, despite the low number of positive
samples, these results could reflect this trend in dogs in
Spain. In addition, these two isolates were also multi-drug
resistant to clindamycin, erythromycin and metronidazole,
a pattern already described in dogs [15, 18]. Overall, these
results suggest that antimicrobial susceptibility surveil-
lance programs should be implemented in C. difficile
strains isolated from dogs since they could be a possible
source of metronidazole-resistant and MDR C. difficile.
However, in vitro results should be interpreted with cau-
tion due to the limited information available regarding
breakpoints for anaerobic microorganisms of veterinary
relevance, and the fact that the antimicrobial intestinal
concentrations are not known for all cases.
The number of resistant isolates to moxifloxacin in
this study was relatively low (1/6), which was expected
due to the low use of this drug in companion animals in
Spain and the low prevalence of resistance to this drug
reported in previous studies in dogs and other animal
species [43]. Although the use of clindamycin and
erythromycin in companion animals in Spain is low [44],
50% and 33.3% of the isolates, respectively, were resist-
ant to them. The resistance to clindamycin and erythro-
mycin is common among C. difficile isolates in dogs
[18]. This feature is mainly associated to ermB genes
which are located in mobile elements, so these results
probably reflect the spread of this determinant among C.
difficile isolates regardless of their origin.
The results regarding strain D24 were unexpected.
Heterogeneous and stable resistance to metronidazole
was observed with high MIC values. The in vitro detec-
tion of subpopulations with reduced susceptibility to this
antibiotic may be related to treatment failure observed
in humans [28]. A similar phenomenon was observed on
erythromycin and clindamycin susceptibility tests. The
reason for these results is not clear and warrants further
molecular studies.
The strain isolated from the lizard (E6) represents a
new ribotype and it belongs to ST347 for which a new
clade (C-III) was proposed [29]. A maximum likelihood
tree was constructed using the E6 strain ST, sequence
types from our C. difficile strain collection and from
PubMLST database (Fig. 1), and it showed that E6 strain
clade is completely apart from the rest of defined and
proposed new clades described until the termination of
this study [29, 45, 46]. E6 seems to be a non-toxigenic
isolate (tcdA, tcdB, cdtA and cdtB negative results by
PCR), but it yielded also a negative result in non-
toxigenic PCR which allows thinking that it has not the
traditional non-coding region which replaces the PaLoc
as it has been described before [45, 47, 48]. Besides, the
possible presence of toxin A and B genes remnants was
analysed by toxinotyping with negative results as well.
Therefore, it seems appropriate to perform whole gen-
ome sequencing analysis to verify the relationship of this
isolate with C. difficile population and to examine its
PaLoc insertion site organisation [48]. It is reasonable to
assume that a new genotype could be introduced in
Spain by an exotic animal species as has happened in
the past with other C. difficile genotypes which have
spread among different continents [49].
Conclusions
In this study, 4.4% toxigenic C. difficile strains were iso-
lated from diarrhoeic dogs. Since the ribotypes found in
dogs are also commonly found in humans, it is possible
Fig. 2 Metronidazole susceptibility test of Clostridium difficile D24
strain after 48 h of incubation. GI, growth I; GII, growth II
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that dogs may act as a source of contamination for hu-
man beings or vice versa. However, further studies are
needed in particular to define the likely role of pets as
vectors, especially in light of the spread of pet therapy
practices. There is also a potential risk for the emer-
gence of C. difficile strains resistant to the first line of
antimicrobial drugs used for the treatment of CDI in
people. Metronidazole is widely used in dogs, thus ani-
mals treated with this drug could be a possible source of
MDR strains for humans. Clostridium difficile antimicro-
bial susceptibility surveillance programs should be ad-
vised in this animal species. Exotic animals can harbour
uncommon C. difficile strains, different than those
already established in the country of destination. The
molecular results observed for E6 C. difficile strain,
which can be also found in companion animal species,
prompt the need for genome sequencing analyses to
study this unusual isolate.
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Additional file 1: cdu1-cdd1 PCR (700 bp) agarose gel image from
Clostridium difficile field isolates. Lane 1 C. difficile E6 strain, lanes 2–6 field
isolates, lane 7 positive control, lane 8 negative control. M: 100 bp
molecular mass (arrows point 500 bp fragment). (JPEG 1439 kb)
Additional file 2: Clostridium difficile field isolates and Clostridium difficile
ATCC 43255 (positive control) toxinotyping in agarose gel. a A1 fragment,
3.1 kb: lane 1 E6 isolate, lanes 2–5 field isolates, lane 6 ATTC strain, lane 7
negative control. b A3 fragment, 3.1 kb: lane 1 ATCC strain, lane 2 E6
strain, lane 3 negative control. c B1 fragment, 3.1 kb: lanes 1 and 3 field
isolates, lane 2 E6 strain, lane 4 ATCC strain, lane 5 negative control. M:
1 kb molecular mass (upper arrows point to 3 kb fragment and lower
arrows point to 1 kb fragment) (JPEG 1765 kb)
Additional file 3: Clostridium difficile field isolates and Clostridium difficile
ATCC 43255 (positive control) toxinotyping in agarose gel. Lanes 1–3 A2
fragment, 2 kb: ATTC strain, E6 strain and negative control respectively;
lanes 4–6 B2 fragment, 2 kb: ATTC strain, E6 strain and negative control
respectively; lanes 7–9 B3 fragment, 2 kb: ATTC strain, E6 strain and negative
control respectively. M: 1 kb molecular mass (upper arrows point to 3 kb
fragment and lower arrows point to 1 kb fragment) (JPEG 839 kb)
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